Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) Sees Large Growth in Short Interest

Share on StockTwits

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 3,810,000 shares, a growth of 32.8% from the September 30th total of 2,870,000 shares. Based on an average trading volume of 1,470,000 shares, the short-interest ratio is presently 2.6 days. Currently, 2.5% of the company’s shares are short sold.

NYSEAMERICAN ATNM opened at $0.25 on Thursday. Actinium Pharmaceuticals has a 12 month low of $0.19 and a 12 month high of $0.71.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.04) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.04).

A number of research firms have recently commented on ATNM. William Blair began coverage on shares of Actinium Pharmaceuticals in a report on Thursday, August 8th. They issued an “outperform” rating on the stock. Zacks Investment Research cut shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 15th. Finally, Maxim Group restated a “buy” rating and issued a $1.50 price target on shares of Actinium Pharmaceuticals in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $3.19.

An institutional investor recently raised its position in Actinium Pharmaceuticals stock. Oppenheimer & Co. Inc. boosted its holdings in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 34.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 236,281 shares of the biotechnology company’s stock after acquiring an additional 60,769 shares during the period. Oppenheimer & Co. Inc. owned about 0.15% of Actinium Pharmaceuticals worth $58,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Read More: What does relative strength index mean?

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.